Selexis CHO Cells in Suspension-1

Videos

Selexis enables biopharmaceutical companies to produce virtually any recombinant therapeutic protein, because we have the ability to understand and modify our cells to address productivity and expression challenges.

Protein Expression Issues: SURE CHO-MPLUS Libraries

SEPTEMBER 29, 2017

Leveraging our knowledge of the data from the Selexis SURE CHO-M genome and transcriptome, we identified areas within the CHO-M secretory pathways that could be modified to address particular issues such as stalled translocation, improper folding, incomplete post-translational modifications, chromosomal instability or insufficient cellular respiration to handle the increased protein load.
Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.
From ubiquitous immunoglobulin-based drugs such as monoclonal and bispecific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™

Selexis Monoclonal Antibodies block

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.

Learn More
Selexis Difficult-to-Express Proteins block

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis Bispecific Antibodies block

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More
Selexis SA footer Logo

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

A JSR Life Sciences Company Logo
EN-BEST MEDIUM WORKPLACES_CMYK

Latest News

October 31, 2022

KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer

Read More
September 8, 2022

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Read More

Copyright© 2023 Selexis SA. All Rights Reserved.